Replacing Actinomycin-D with Carboplatin for Newly Diagnosed Rhabdomyosarcoma

Sezgin, Gulay; Acipayam, Can; Bayram, Ibrahim; Ozkan, Ayse; Kupeli, Serhan; Tanyeli, Atila

추천

검색

자료유형: 학술저널

저자정보: Sezgin, Gulay (Division of Pediatric Oncology and BMT Unit, Cukurova University Medical School) Acipayam, Can (Division of Pediatric Oncology and BMT Unit, Cukurova University Medical School) Bayram, Ibrahim (Division of Pediatric Oncology and BMT Unit, Cukurova University Medical School) Ozkan, Ayse (Division of Pediatric Oncology and BMT Unit, Cukurova University Medical School) Kupeli, Serhan (Division of Pediatric Oncology and BMT Unit, Cukurova University Medical School) Tanyeli, Atila (Division of Pediatric Oncology and BMT Unit, Cukurova University Medical School)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제8호

발행연도: 2015.1

수록면: 3,351 - 3,354 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric age group. All patients with RMS regardless of their initial stage or group receive combination chemotherapy as 'standard therapy' consisting of vincristine, actinomycin-D and cyclophosphamide. Actinomycin-D was not readily available in Turkey at one time. Carboplatin was used instead in order to prevent delays in treatment. The aim of this report is to present the results of patients with rhabdomyosarcoma receiving carboplatin or actinomycin-D therapy. Materials and Methods: Twenty four patients with rhabdomyosarcoma treated between December 2000 and June 2011 were included in this retrospective study. The patients were treated according to International Rhabdomyosarcoma Study Group guidelines. Eleven patients were treated with actinomycin-D and 13 with carboplatin ($250mg/m^2/dose$ for 2 days). The two groups were then compared in terms of 2- and 5-year overall survival (OS) and hematological and non-hematological toxicities. Results: Age, sex, stage and the mean duration of follow-up were similar in both groups (p>0.05). Two- and five-year OS levels were 68.2% in the carboplatin group and 78.0% and 40.0%, respectively, in the actinomycin-D group. There was no statistical difference in the number of febrile episodes (p=0.86) and no other hematological and non-hematological adverse effects were recorded in both groups. Conclusions: The findings show that carboplatin can be used as an alternative drug in the primary treatment of rhabdomyosarcoma in the event that actinomycin-D is unavailable or not tolerated.

#Carboplatin #actinomycin-D #rhabdomyosarcoma chemotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!